New hope for retinitis pigmentosa patients: expanded access to OCU400
NCT ID NCT06574997
First seen Apr 15, 2026 · Last updated May 14, 2026 · Updated 5 times
Summary
This program provides OCU400, an experimental treatment, to up to 75 adults with retinitis pigmentosa who cannot join the main Phase 3 trial. The goal is to offer access to those with no other FDA-approved options. Participants must have a confirmed genetic diagnosis and evidence of remaining photoreceptor cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advanced Research
Deerfield Beach, Florida, 33064, United States
-
Associated Retina Consultants
Phoenix, Arizona, 85020, United States
-
Erie Retina Research
Erie, Pennsylvania, 16507, United States
-
Gundersen Health
La Crosse, Wisconsin, 54601, United States
Conditions
Explore the condition pages connected to this study.